China Universal Asset Management Co., Ltd. Wave Life Sciences Ltd. Transaction History

China Universal Asset Management Co., Ltd.

$773 Million
Q1 2024

A detailed history of China Universal Asset Management Co., Ltd. transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 23,473 shares of WVE stock, worth $128,397. This represents 0.02% of its overall portfolio holdings.

Number of Shares

23,473

Previous 23,473 -0.0%

Holding current value

$128,397

Previous $145,000 0.69%

% of portfolio

0.02%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$3.54 - $6.84 $42,540 - $82,196	12,017 Added 104.9%	23,473 $145,000
Q4 2023 May 21, 2024	SELL	$4.16 - $6.87 $49,990 - $82,556	-12,017 Reduced 51.19%	11,456 $57,000
Q4 2023 Jan 23, 2024	BUY	$4.16 - $6.87 $37,107 - $61,280	8,920 Added 351.74%	11,456 $58,000
Q3 2023 May 21, 2024	BUY	$3.56 - $5.75 $4,439 - $7,170	1,247 Added 96.74%	2,536 $14,000
Q3 2023 Oct 30, 2023	BUY	$3.56 - $5.75 $4,439 - $7,170	1,247 Added 96.74%	2,536 $15,000

Q2 2023 May 21, 2024	SELL	$3.51 - $4.69 $126 - $168	-36 Reduced 2.72%	1,289 $4,000
Q2 2023 Jul 27, 2023	SELL	$3.51 - $4.69 $126 - $168	-36 Reduced 2.72%	1,289 $5,000
Q1 2023 May 21, 2024	BUY	$3.58 - $6.3 $1,582 - $2,784	442 Added 50.06%	1,325 $5,000
Q1 2023 Apr 27, 2023	BUY	$3.58 - $6.3 $1,582 - $2,784	442 Added 50.06%	1,325 $6,000
Q4 2022 May 21, 2024	SELL	$3.18 - $7.0 $71,836 - $158,130	-22,590 Reduced 96.24%	883 $6,000
Q4 2022 Jan 31, 2023	BUY	$3.18 - $7.0 $222 - $490	70 Added 8.61%	883 $6,000
Q3 2022 Oct 21, 2022	BUY	$2.37 - $4.28 $1,926 - $3,479	813 New	813 $3,000

Others Institutions Holding WVE

# of Institutions

132

Shares Held

71.8M

Call Options Held

86.1K

Put Options Held

20.1K

View Full List

About Wave Life Sciences Ltd.

Ticker WVE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,820,096
Market Cap $475M
Description
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...

More about WVE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account

China Universal Asset Management Co., Ltd. Wave Life Sciences Ltd. Transaction History